Cibc World Market Inc. Acquires New Stake in Charles River Laboratories International, Inc. (NYSE:CRL)

Cibc World Market Inc. acquired a new stake in shares of Charles River Laboratories International, Inc. (NYSE:CRLGet Rating) in the second quarter, HoldingsChannel.com reports. The firm acquired 1,782 shares of the medical research company’s stock, valued at approximately $381,000.

A number of other hedge funds also recently bought and sold shares of the company. Arizona State Retirement System increased its position in Charles River Laboratories International by 0.3% during the second quarter. Arizona State Retirement System now owns 14,090 shares of the medical research company’s stock valued at $3,015,000 after acquiring an additional 43 shares during the last quarter. Wetherby Asset Management Inc. increased its position in Charles River Laboratories International by 2.5% during the first quarter. Wetherby Asset Management Inc. now owns 1,793 shares of the medical research company’s stock valued at $509,000 after acquiring an additional 44 shares during the last quarter. CIBC Asset Management Inc increased its position in Charles River Laboratories International by 1.0% in the first quarter. CIBC Asset Management Inc now owns 4,783 shares of the medical research company’s stock worth $1,358,000 after buying an additional 47 shares in the last quarter. Blue Chip Partners Inc. increased its position in Charles River Laboratories International by 4.1% in the first quarter. Blue Chip Partners Inc. now owns 1,256 shares of the medical research company’s stock worth $357,000 after buying an additional 49 shares in the last quarter. Finally, Sumitomo Mitsui DS Asset Management Company Ltd increased its position in Charles River Laboratories International by 1.6% in the second quarter. Sumitomo Mitsui DS Asset Management Company Ltd now owns 3,121 shares of the medical research company’s stock worth $668,000 after buying an additional 50 shares in the last quarter. Hedge funds and other institutional investors own 95.20% of the company’s stock.

Insider Activity at Charles River Laboratories International

In related news, EVP Joseph W. Laplume sold 534 shares of the stock in a transaction that occurred on Friday, November 4th. The stock was sold at an average price of $216.36, for a total transaction of $115,536.24. Following the completion of the transaction, the executive vice president now directly owns 20,232 shares of the company’s stock, valued at $4,377,395.52. The sale was disclosed in a filing with the SEC, which is available through this link. In related news, EVP Shannon M. Parisotto sold 2,279 shares of the stock in a transaction that occurred on Tuesday, November 15th. The stock was sold at an average price of $249.90, for a total transaction of $569,522.10. Following the completion of the transaction, the executive vice president now directly owns 2,499 shares of the company’s stock, valued at $624,500.10. The sale was disclosed in a filing with the SEC, which is available through this link. Also, EVP Joseph W. Laplume sold 534 shares of the stock in a transaction that occurred on Friday, November 4th. The shares were sold at an average price of $216.36, for a total value of $115,536.24. Following the transaction, the executive vice president now directly owns 20,232 shares of the company’s stock, valued at $4,377,395.52. The disclosure for this sale can be found here. Over the last three months, insiders sold 3,668 shares of company stock valued at $897,603. Insiders own 1.10% of the company’s stock.

Analyst Upgrades and Downgrades

A number of analysts have commented on CRL shares. Evercore ISI reduced their price target on Charles River Laboratories International to $260.00 in a research report on Tuesday, August 9th. Jefferies Financial Group upgraded Charles River Laboratories International from a “hold” rating to a “buy” rating and set a $240.00 price target for the company in a research report on Thursday, September 29th. Credit Suisse Group reduced their price target on Charles River Laboratories International from $285.00 to $280.00 and set an “outperform” rating for the company in a research report on Thursday, November 3rd. StockNews.com started coverage on Charles River Laboratories International in a research report on Wednesday, October 12th. They issued a “hold” rating for the company. Finally, William Blair restated an “outperform” rating on shares of Charles River Laboratories International in a research report on Wednesday, November 2nd. Three investment analysts have rated the stock with a hold rating and twelve have given a buy rating to the stock. According to MarketBeat, Charles River Laboratories International presently has a consensus rating of “Moderate Buy” and an average price target of $298.42.

Charles River Laboratories International Stock Performance

NYSE CRL opened at $242.13 on Wednesday. The firm has a market cap of $12.32 billion, a price-to-earnings ratio of 28.52, a price-to-earnings-growth ratio of 1.59 and a beta of 1.28. The company has a quick ratio of 1.14, a current ratio of 1.40 and a debt-to-equity ratio of 1.12. The business has a 50-day moving average price of $210.85 and a 200-day moving average price of $218.91. Charles River Laboratories International, Inc. has a twelve month low of $181.36 and a twelve month high of $385.11.

Charles River Laboratories International Profile

(Get Rating)

Charles River Laboratories International, Inc, a non-clinical contract research organization, provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).

Featured Stories

Want to see what other hedge funds are holding CRL? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Charles River Laboratories International, Inc. (NYSE:CRLGet Rating).

Institutional Ownership by Quarter for Charles River Laboratories International (NYSE:CRL)

Receive News & Ratings for Charles River Laboratories International Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Charles River Laboratories International and related companies with MarketBeat.com's FREE daily email newsletter.